Regulus Therapeutics Inc. (RGLS)
2.83
0.29 (11.20%)
At close: Apr 24, 2025, 12:14 PM
11.20% (1D)
| Bid | 2.82 |
| Market Cap | 187.8M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -46.36M |
| EPS (ttm) | -0.9 |
| PE Ratio (ttm) | -3.15 |
| Forward PE | -1.66 |
| Analyst | Buy |
| Ask | 2.85 |
| Volume | 1,099,252 |
| Avg. Volume (20D) | 1,232,226 |
| Open | 2.60 |
| Previous Close | 2.54 |
| Day's Range | 2.58 - 2.85 |
| 52-Week Range | 0.83 - 2.90 |
| Beta | 1.02 |
About RGLS
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 9, 2012
Employees 34
Stock Exchange NASDAQ
Ticker Symbol RGLS
Website https://www.regulusrx.com
Analyst Forecast
According to 5 analyst ratings, the average rating for RGLS stock is "Buy." The 12-month stock price forecast is $7.5, which is an increase of 164.55% from the latest price.
Stock Forecasts4 weeks ago
+16.28%
Regulus Therapeutics shares are trading higher aft...
Unlock content with
Pro Subscription
10 months ago
-18.33%
Regulus Therapeutics shares are trading lower after the company announced results in the Phase 1b Study for ADPKD treatment. The stock initially traded higher, but it has since reversed.
